Apollo Hospitals Enterprise Limited announced the outcome of its Board Meeting held on February 10, 2026. The Board declared an interim dividend of Rs. 10/- per share for FY2025-26. The company also disclosed strong financial results for the three and nine months ending December 31, 2025. Consolidated revenue grew 17% YoY for the quarter, and Profit After Tax (PAT) surged 35% YoY to Rs. 502 Crore.
Board Declares Interim Dividend
The Board of Directors of Apollo Hospitals Enterprise Limited has approved the declaration of an interim dividend of Rs. 10/- per share (representing 200% of the face value of Rs. 5/- per share) for the financial year ending March 31, 2026. The record date for this dividend payment has been fixed as February 16, 2026, with the payment scheduled on or before February 27, 2026.
Unaudited Standalone Financial Performance (Q3 FY2026)
The unaudited standalone results for the quarter ended December 31, 2025, showed robust performance:
- Total Income (Standalone) reached Rs. 24,717 Million, up from Rs. 21,627 Million in the corresponding quarter last year.
- Profit After Tax (PAT) for the quarter stood at Rs. 3,811 Million, compared to Rs. 3,391 Million in the previous year’s quarter.
- Year-to-date standalone PAT reached Rs. 11,055 Million.
- Basic and diluted Earnings Per Share (EPS) for the quarter were *Rs. 26.67.
Unaudited Consolidated Financial Performance (Q3 FY2026 Highlights)
The consolidated results reflected strong growth across all business verticals. Key highlights for the quarter (Q3 FY26) versus the previous year (Q3 FY25) include:
- Consolidated Revenue: Rs. 6,477 Crore, a growth of 17% YoY (compared to Rs. 5,527 Crore).
- Consolidated EBITDA: Rs. 965 Crore, a growth of 27% YoY (compared to Rs. 762 Crore).
- Consolidated PAT: Rs. 502 Crore, a surge of 35% YoY (compared to Rs. 372 Crore).
- Diluted EPS: Rs. 34.94 per share (not annualized).
- GMV of Apollo 24/7 reached Rs. 525 Crore.
Year-to-Date (YTD Dec FY26) Consolidated PAT grew 34% YoY to Rs. 1,412 Crore.
Segmental Performance Deep Dive
Healthcare Services (Hospitals)
This segment showed sustained clinical execution:
- Revenue grew 14% YoY to Rs. 3,183 Crore in Q3FY26.
- EBITDA grew 18% YoY to Rs. 790 Crore, with margins at 24.8%.
- PAT stood at Rs. 422 Crore, up 21% YoY.
- The company had 8,072 operating beds, with overall occupancy at 67%.
Apollo HealthCo (Digital & Pharmacy)
The digital and retail segment achieved significant scale:
- Revenue grew 20% YoY to Rs. 2,827 Crore.
- EBITDA reached Rs. 128 Crore, significantly higher than Rs. 57 Crore in Q3FY25.
- 185 net new stores were opened this quarter, bringing the total to 7,113 stores.
Apollo Health and Lifestyle Limited (Diagnostics and Retail)
- Gross Revenue grew 20% YoY to Rs. 467 Crore.
- EBITDA margins improved to 10.2%.
Operational and Clinical Milestones
The release highlighted several achievements demonstrating clinical depth:
- Transformational Paediatric Breakthrough: Successful treatment of a 13-month-old with Spinal Muscular Atrophy (Type 1) using gene therapy at Chennai.
- New Launches: Opened a 250-bed quaternary care hospital in Pune and launched advanced multi-robot surgery centers in Delhi.
- Transplant Leadership: The transplant program achieved milestones including over 21,000 kidney transplants and 5,000 liver transplants cumulatively.
- The Board also approved a Business Framework Agreement on June 30, 2025, related to the Composite Scheme of Arrangement concerning its pharmacy and digital health businesses.
Awards and Accolades
Apollo Hospitals received numerous recognitions, including the Economic Times Award 2025 in five categories for its Chennai Main facility, and multiple CII TN Healthcare Excellence Honours’25.
Source: BSE
